This brochure gives an overview of the Mental Health Parity and Addiction Equity Act of 2008. It lists some of the common limits placed on mental health and substance use disorder benefits and services.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This updated workbook is a companion piece to the Anger Management Manual; it summarizes the information presented in each session of the 12-week program and provides worksheets for completing exercises.

This updated manual contains a 12-week cognitive–behavioral anger management group treatment model. The content includes specific instructions and suggested remarks for group leaders, and exercises for group members. This model will work in a variety of clinical settings, and with diverse audiences.

This poster is for clients and their family members in OUD treatment who are pregnant or who are currently not pregnant but of childbearing age.

This fact sheet is for women who are pregnant or of childbearing age with an opioid use disorder

This pamphlet addresses the health benefits that can come with quitting smoking while recovering from substance use disorder.

This fact sheet serves as a guide for individuals seeking behavioral health treatment. It provides three necessary steps to complete prior to utilizing a treatment center and the five signs of a quality treatment center, which include a review of the accreditation, medication, evidence-based practices, position on the role of families, and support networks.

This publication provides an overview of federal disclosure laws affecting private-sector, employer sponsored group health plans and health insurers. This document is not a comprehensive description of these laws and should not be considered legal advice.